Invizius treats first patients with lead dialysis product H-Guardยฎ
Invizius Limited, a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guardยฎ Priming Solution, in the Companyโs first-in-human Phase 1 clinical study. The UK